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Background.F a c t o r sa ﬀecting outcomes after orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC) have
been extensively studied, but some of them have only recently been discovered or reassessed. Methods. We analyzed classical and
more recently emerging variables with a hypothetical impact on recurrence-free survival (RFS) in a single-center series of 283
patientstransplantedforHCCbetween1997and2009.Results.Five-yearpatientsurvivalandRFSwere75%and86%,respectively.
Thirty-four (12%) patients had HCC recurrence. Elevated preoperative alpha-fetoprotein (AFP) levels, preoperative treatments
of HCC, unfulﬁlled Milan and up-to-seven criteria at ﬁnal histology, poor tumor diﬀerentiation, and tumor microvascular
invasion negatively aﬀected RFS by univariate analysis. Milan and up-to-seven criteria applied preoperatively, and the use of
m-TOR inhibitors did not reach statistical signiﬁcance. Cox’s proportional hazard model showed that only elevated AFP levels
(Odds Ratio = 2.88; 95%C.I. = 1.43–5.80; P = .003), preoperative tumor treatments (Odds Ratio = 4.84; 95%C.I. = 1.42–
16.42; P = .01), and microvascular invasion (Odds Ratio = 4.82; 95%C.I. = 1.87–12.41; P = .001) were predictors of lower
RFS. Conclusions. Biological aggressiveness and preoperative tumor treatment, rather than traditional and expanded dimensional
criteria, conditioned the outcomes in patients transplanted for HCC.
1.Introduction
Hepatocellular carcinoma (HCC) is one of the ﬁve most
common malignancies and its frequency is increasing in
Western countries [1]. Within well-accepted criteria, liver
transplantation represents the treatment of choice for
patients with HCC on cirrhosis [2].
After the introduction of the so-called Milan criteria
(MC), clinical outcomes after orthotopic liver transplan-
tation (OLT) for HCC drastically improved compared to
the previous era, where the inappropriate patient selection
generally led to dismal results [2]. However, using MC does
not completely eliminate the risk of recurrence [3, 4], while
the increasing number of patients with HCC on cirrhosis
with a potential beneﬁt from OLT pushed some centers to
expand classical MC, with acceptable results [5].
Cancer recurrence is greatly aﬀected by factors diﬀerent
from tumor size and number, depicting a more aggressive
tumor behavior, such as vascular invasion and poor diﬀer-
entiation [4, 6–8].
Recently, newly proposed dimensional criteria based on
histology of the explanted native liver showed that a moder-
ate expansion of the MC is possible, without worsening the
prognosis [6]. One major criticism to these ﬁndings is that,2 Journal of Transplantation
due to the still imperfect preoperative imaging techniques,
preoperative patient selection with enlarged criteria can not
be safely proposed [9].
The impact of the posttransplant immunosuppression
on tumor recurrence has recently been outlined, and some
authors demonstrated a beneﬁcial eﬀect of Mammalian
Target Of Rapamycin (m-TOR) inhibitors in the clinical
setting [10, 11]. However, prospective randomized studies
conﬁrmingthesaferuseofthesedrugscomparedtostandard
immunosuppressive schedules in patients with HCC are
lacking.
In the present study, we analyzed the outcomes in terms
of tumor recurrence, recurrence-free survival (RFS), and
disease-free survival (DFS) of a single-center series of OLTs
for HCC by including traditional risk factors and those
ﬁndings were recently discussed as possible determinants of
prognosis, such as up-to-seven criteria [6] and the use of m-
TOR inhibitors.
2.MaterialandMethods
Between January 1997 and September 2009, a total of 289
patients received orthotopic liver transplantation (OLT) at
our department with a preoperative diagnosis of HCC.
Of these 289 patients, 6 (2%) died within one month
after OLT without evidence of HCC recurrence and were
excluded from the analysis, while the remaining 283 (98%)
formed the study population. All data were collected from a
prospectively updated database.
Preoperative diagnosis of HCC was obtained as pre-
viously reported [7]. The diagnosis of HCC was made
preoperativelyfollowingtheEASLandtheAASLDguidelines
[12, 13]. Nodules between 1 and 2cm were considered HCCs
when two radiological techniques among ultrasonography
(US), computed tomography (CT), and magnetic resonance
imaging (MRI) showed a typical hypervascular pattern with
a washout in the venous phase. Nodules less than 2cm
with an equivocal imaging pattern were biopsied whenever
possible, and, if the biopsy was technically unfeasible, they
were included in a US and CT scan surveillance program.
The diagnosis of HCC was the only indication for LT in 16
cases (5%), while in the remaining cases it was associated
with liver failure due to cirrhosis. During the waiting time,
preoperative treatments were decided in each patient by a
multidisciplinary team according to the tumor stage, HCC
location, and liver function. Patients with a single nodule or
two nodules located in the same segment and preserved liver
function were treated by liver resection. Patients not suitable
for liver resection were treated by transarterial chemo-
embolization (TACE), percutaneous alcohol injection (PEI),
or radiofrequency ablation (RF) aiming at achieving com-
plete tumor necrosis. Some patients were treated by diﬀerent
modalities over time.
Throughout the study period, patients were included in
the waiting list for OLT only if meeting the Milan criteria
(MC). In selected cases, patients not meeting the MC were
included in the waiting list after completing a down-staging
protocol, as previously reported in [7]. A total of 39 (14%)
patients were downstaged and transplanted.
The policy of our center in including/maintaining each
patient in the waiting list is based on the fulﬁlling of the
MC by considering only entirely or partially viable nodules,
and not completely treated nodules, at any radiological
evaluation. For example, one patient presenting with 4
noduleslessthan3cmindiametercouldenterthewaitinglist
even if, after treatment and a subsequent followup of at least
3months,onlyonenoduleshowedcompleteresponsewithin
the down-staging protocol. Even without being initially
downstaged, patients developing multiple nodules during
their history could be maintained in the waiting list if, at
the more recent radiological assessment, previous lesion(s)
had been successfully treated, and the still viable tumor(s)
fulﬁlled the MC, provided that the total computation of
nodules did not exceed criteria for down-staging during the
entire patient surveillance [7].
However, for the purpose of the present study, MC and
up-to-seven criteria were applied to all tumors (either still
viable or completely treated) as detected by preoperative
imaging in an intention-to-treat approach from the time of
presentation to the date of transplant. Indeed, apparently
necrotic lesions may display residual foci of viability at ﬁnal
histology.
When listed, patients with all tumor stages were followed
with US, alpha-fetoprotein (AFP) determination, and CT
scan or MRI repeated at least every 3 months.
After OLT, patients were followed-up with dosage of
serum AFP level and hepatic US every 3 months, and with
abdominal CT scan and chest X-ray every 6 months. In
the case of suspected tumor recurrence, CT and/or MRI
were performed. In selected cases, bone scan, positron
emission tomography scan, angiography of the celiac trunk
with Lipiodol injection, and, if necessary, liver biopsy were
performed.
Severity of liver dysfunction was graded according to
the real Model for End-stage Liver Disease (MELD) score
currently in use by UNOS (http://www.unos.org/)[ 14]. This
score was retrospectively applied to patients transplanted
before 2001.
Hepatitis B infection was deﬁned as the positivity of
hepatitis B surface antigen (HBsAg) or of anticore antibodies
(HBcAb) at the time of surgery. Hepatitis C infection was
deﬁned as the positivity for serum anti-HCV antibodies.
2.1. Statistical Analysis. Results were expressed as median
andrangeofvalues.Diﬀerencesintumorrecurrencebetween
groups were calculated with the with the chi-square or
the Fisher exact test, when appropriate. The Kaplan-Meier
method was used for the analysis of prognostic factors
for RFS and DFS, and the diﬀerences between groups
were compared by the log-rank test. Overall survival was
computed from the day of surgery to the day of death or
the last follow-up visit. RFS was computed from the day
of surgery to the date of detection of tumor recurrence,
and patients who died due to causes unrelated to tumor
recurrence were censored at the date of death. DFS wasJournal of Transplantation 3
Table 1:Demographic,clinical,andpathologicalparametersof283
patients with HCC receiving OLT at the Bologna Center between
1997 and 2009.
Variables
Gender
Male 241 (85%)
Female 42 (15%)
Median age (years) 57 (33–68)
Viral infection
HCV-positive 152 (54%)
HBV-positive 70 (25%)
HCV, HBV-positive 13 (5%)
HCV, HBV-negative 48 (17%)
Median real MELD score 15 (6–45)
Preoperative treatments 222 (78%)
TACE 158 (56%)
PEI 30 (10%)
RF 63 (22%)
Liver resection 16 (6%)
Median AFP level at OLT (ng/mL) 9 (1–6826)
Median preoperative tumor number 2 (1–6)
Median preoperative tumor diameter (cm) 2.5 (0.8–5)
Down-staging to MC 39 (14%)
Fulﬁlling MC at OLT 224 (79%)
Fulﬁlling up-to-7 criteria at OLT 267 (94%)
Median tumor number at histology 1 (0–12)
Median tumor diameter at histology (cm) 2.5 (0–6)
Fulﬁlling MC at histology 208 (73%)
Fulﬁlling up-to-7 criteria at histology 249 (88%)
Tumor grading
G0–G2 143 (50.5%)
G3–G4 140 (49.5%)
Microvascular invasion 117 (41%)
Macrovascular invasion 3( 1 % )
Post-OLT M-TOR inhibitors 43 (15%)
HCC: hepatocellular carcinoma. OLT: orthotopic liver transplantation.
HCV:hepatitisCvirus.HBV:hepatitisBvirus.MELD:ModelforEnd-stage
Liver Disease. TACE: trans-arterial chemoembolization. PEI: percutaneous
alcohol injection. RF: radiofrequency ablation. AFP: alpha-fetoprotein.
MC: Milan criteria.
computed from the day of surgery to the date of detection
of tumor recurrence or patient death in the case of no
recurrence. Variables achieving statistical signiﬁcance at
the univariate analysis were put in the multivariate Cox’s
proportional hazard model (for RFS). A P-value <. 05 was
considered statistically signiﬁcant. Statistical analysis was
carried out with the SPSS software packaging (SPSS Inc.,
Chicago, IL, USA), version 13.
3. Results
3.1. Characteristics of the Study Population. Patient charac-
teristics are reported in Table 1. There were 241 (85%) males
a n d4 2( 1 5 % )f e m a l e s .M e d i a na g ew a s5 7y e a r s( r a n g e :3 3 –
68). Most patients (54%) had isolated HCV infection, while
median MELD score was 15 (range: 6–45).
The large majority of patients (78%) received
preoperative treatments in order to control tumor
growth/invasiveness and to prevent a drop out from
the waiting list. TACE was performed in 56% of patients,
while PEI, RF, and liver resection were oﬀered to a minority
of subjects.
Preoperatively, 79% and 94% of patients fulﬁlled the MC
and the up-to-seven criteria (i.e., the sum of total number
of tumors plus the diameter of the largest nodule in cm
not exceeding the value of 7) [6], respectively. The above
percentages changed to 73% and to 88%, respectively, at the
ﬁnal histology of the native liver.
A discrepancy between preoperative and postoperative
MC was found in 80 (28%) patients, with 48 (17%) patients
being under-staged and 32 (11%) being over-staged. A
divergence between preoperative and postoperative up-to-
seven criteria was present in 34 (12%) patients, with 30
(11%) patients being under-staged and 12 (4%) being over-
staged.
Poorly diﬀerentiated tumors according to the Edmon-
son classiﬁcation [15] were found in nearly 50% of
patients, while microvascular and macrovascular invasion
were observed in 41% and in 1% of patients, respectively.
Postoperatively, m-TOR inhibitors (sirolimus or
everolimus) were used in 43 (15%) patients as primary
immunosuppressant drugs or in combination with reduced
doses of calcineurin inhibitors (tacrolimus or cyclosporine).
The indications for using m-TOR inhibitors were side-
eﬀects of calcineurin inhibitors and/or histological evidence
of HCC at high risk of recurrence [11]. Therapeutic levels of
either sirolimus or everolimus were targeted at 3 to 8ng/mL
in all patients.
3.2. Survival Analysis. Median followup was 42 months
(range: 1–152). At the end of followup, 214 (76%) patients
were alive, and 69 (24%) had died. Causes of death were
HCC recurrence in 27 (9%) cases, hepatitis recurrence in 15
(5%) cases, infections in 7 (2%) cases, multiorgan failure in
7 (2%) cases, other de novo t u m o r si n3( 1 % )c a s e s ,r e j e c t i o n
in 1 (0.4%) case, and other causes in 9 (3%) cases. Overall
3-year and 5-year patient survival rates were 81% and 75%,
respectively.
Thirty-four (12%) patients had HCC recurrence at a
median time from transplant of 12 months (range: 1–
118). In 2 cases, HCC recurrence occurred 7 and 9 years
after OLT, respectively, and it was thought to be related to
posttransplant hepatitis C recurrence.
The initial sites of tumor recurrence were liver in 3 cases,
lung in 3 cases, peritoneum in 2 cases, and bone in 2 cases;
multiple sites were simultaneously involved in the remaining
24 cases. Overall 3-year and 5-year RFS rates were 88% and4 Journal of Transplantation
Table 2: Univariate analysis of factors aﬀecting recurrence-free survival after OLT in patients with HCC.
Variables 3-yr survival 5-yr survival P value
Gender Female (n = 42) 82% 82% .1
Male (n = 241) 89% 87%
Age
≤ 60 years (n = 184) 88% 87% .9
> 60 years (n = 99) 89% 85%
AFP > 30ng/mL at OLT No (n = 201) 92% 91% <.0001
Yes (n = 78) 76% 74%
Viral infection
HCV-positive (n = 152) 85% 83%
.4 HBV-positive (n = 70) 88% 88%
HCV, HBV-positive (n = 13) 92% 92%
HCV, HBV-negative (n = 48) 98% 94%
Down-staging to MC No (n = 243) 89% 88% .2
Yes (n = 39) 83% 79%
Preoperative MC Fulﬁlled (n = 224) 90% 89% .07
Not fulﬁlled (n = 59) 81% 77%
Preoperative up-to-seven Fulﬁlled (n = 267) 88% 86% .9
Not fulﬁlled (n = 16) 86% 86%
Pre-OLT treatments No (n = 53) 96% 94% .05
Yes (n = 222) 86% 84%
Histological MC Fulﬁlled (n = 208) 94% 92% <.0001
Not fulﬁlled (n = 75) 73% 71%
Histological up-to-seven Fulﬁlled (n = 249) 91% 89% <.0001
Not fulﬁlled (n = 34) 69% 65%
Grading G0–G2 (n = 143) 96% 95% <.0001
G3–G4 (n = 140) 80% 78%
Microvascular invasion No (n = 166) 97% 96% <.0001
Yes (n = 117) 76% 73%
Macrovascular invasion No (n = 280) 88% 87% .07
Yes (n = 3) 67% 67%
Post-OLT m-TOR inhibitors No (n = 240) 89% 87% .2
Yes (n = 43) 81% 81%
OLT: orthotopic liver transplantation. HCC: hepatocellular carcinoma. AFP: alpha-fetoprotein. MC: Milan criteria. M-TOR: Mammalian Target Of
Rapamycin.
Table 3: Multivariate analysis of factors aﬀecting recurrence-free
survival after OLT in patients with HCC.
P value Odds Ratio C.I. 95%
AFP > 30ng/mL at OLT .003 2.88 1.43–5.80
Pre-OLT treatments .01 4.84 1.42–16.42
Histological up-to-7 .7 0.84 0.32–2.18
Grading .4 1.43 0.56–3.65
Microvascular invasion .001 4.82 1.87–12.41
OLT: orthotopic liver transplantation. HCC: hepatocellular carcinoma.
AFP: alpha-fetoprotein.
86%, respectively. Overall 3-year and 5-year DFS rates were
78% and 74%, respectively.
In all cases, the treatment of recurrence consisted in
systemic chemotherapy with diﬀerent schedules, including
one patient treated with sorafenib. Combined treatments
were liver resection (2 cases), radiotherapy (one case), RF
(one case), and intra-arterial chemotherapy (one case).
Median patient survival after recurrence was 8 months
(range: 0–36).
3.3.PrognosticFactorsforRecurrence-FreeSurvivalandTumor
Recurrence. Patientgenderandsex,preoperativeAFP(witha
cutoﬀ set at 30ng/mL, according to our previous experience)
[7, 16], type of viral infection, fulﬁlling of MC at OLT, pre-
operativetreatments,preoperativedown-staging,fulﬁllingof
MC at ﬁnal histology of the explanted native liver, tumor
diﬀerentiation, presence of micro- and macrovascular tumor
invasion, and postoperative immunosuppression including
m-TOR inhibitors were all analyzed for their impact on RFS.
Fulﬁlling of the so-called up-to-seven criteria was recently
shown to lead to results comparable to those obtained with
the MC [6, 17]. Therefore, preoperative and postoperative
up-to-seven criteria were also considered in the analysis
(Table 2).Journal of Transplantation 5
Table 4: Analysis of factors aﬀecting one-year tumor recurrence rate in patients with HCC.
Variables One-yr recurrence n (%) P value
Gender Female (n = 42) 10 (24) .3
Male (n = 241) 43 (18)
Age
≤ 60 years (n = 184) 34 (18) .8
> 60 years (n = 99) 19 (19)
AFP > 30ng/mL at OLT No (n = 201) 30 (15) .01
Yes (n = 78) 22 (28)
Viral infection
HCV-positive (n = 152) 30 (20)
.8 HBV-positive (n = 70) 13 (19)
HCV, HBV-positive (n = 13) 3 (23)
HCV, HBV-negative (n = 48) 7 (15)
Down-staging to MC No (n = 243) 46 (19) .8
Yes (n = 39) 7 (18)
Preoperative MC Fulﬁlled (n = 224) 44 (20) .4
Not fulﬁlled (n = 59) 9 (15)
Preoperative up-to-seven Fulﬁlled (n = 267) 51 (19) .7
Not fulﬁlled (n = 16) 2 (12)
Pre-OLT treatments No (n = 53) 4 (7) .02
Yes (n = 222) 47 (21)
Histological MC Fulﬁlled (n = 208) 36 (17) .3
Not fulﬁlled (n = 75) 17 (23)
Histological up-to-seven Fulﬁlled (n = 249) 45 (18) .4
Not fulﬁlled (n = 34) 8 (23)
Grading G0–G2 (n = 143) 23 (16) .2
G3–G4 (n = 140) 30 (21)
Microvascular invasion No (n = 166) 25 (15) .06
Yes (n = 117) 28 (24)
Macrovascular invasion No (n = 280) 52 (19) .4
Yes (n = 3) 1 (33)
Post-OLT m-TOR inhibitors No (n = 240) 47 (20) .3
Yes (n = 43) 6 (14)
OLT: orthotopic liver transplantation. HCC: hepatocellular carcinoma. AFP: alpha-fetoprotein. MC: Milan criteria. M-TOR: Mammalian Target Of
Rapamycin.
Elevated AFP levels, preoperative treatments, unfulﬁlled
postoperative MC and up-to-seven criteria, poor tumor
diﬀerentiation, and presence of microvascular invasion were
all predictors of lower RFS by univariate analysis (Table 2).
Since fulﬁlling of postoperative MC and up-to-seven
criteria were conﬁrmed to oﬀer similar survival rates in our
series, the former variable was not put into the multivariate
analysis.
Cox’s proportional hazard model showed that only
elevated AFP levels (Odds Ratio = 2.88; 95% C.I. = 1.43–
5.80; P = .003), preoperative tumor treatments (Odds Ratio
= 4.84; 95% C.I. = 1.42–16.42; P = .01), and microvascular
invasion (Odds Ratio = 4.82; 95% C.I. = 1.87–12.41; P =
.001) were predictors of lower RFS (Table 3).
The same above reported variables were investigated as
putative predictive factors for tumor recurrence within one
year from transplant (Table 4). Elevated preoperative AFP
levelsandpreoperativetumortreatmentwerecorrelatedwith
higher one-year recurrence rates.
Three- and 5-year overall survival and RFS rates of 48
p a t i e n t su n d e r s t a g e dw i t hr e g a r dt op r e o p e r a t i v eM Cw e r e
73% and 67% and 79% and 76%, respectively.
Three- and 5-year overall survival and RFS rates of 30
patientsunderstagedwithregardtopreoperativeup-to-seven
criteria were 62% and 58% and 68% and 64%, respectively.
3.4. Eﬀect of Down-Staging, Milan Criteria, and Up-To-Seven
Criteria. Regarding patients included in the down-staging
protocol, 3- and 5-year RFS of 21 patients fulﬁlling MC at
ﬁnalhistologywassigniﬁcantlybetterthanRFSof18patients
not fulﬁlling MC (95% and 95% versus 69% and 62%, resp.;
P = .02).
Three- and 5-year DFS rates of patients receiving dow-
staging, of patients fulﬁlling preoperative MC and receiving
preoperative treatments, and of patients within preoperative
MC and receiving no preoperative treatment were 76% and
64%, 76% and 74%, and 84% and 82%, respectively (P =
.3). By considering only patients fulﬁlling preoperative MC,6 Journal of Transplantation
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Figure 1: Disease-free survival of patients within preoperative MC
(n = 224), beyond preoperative MC but within up-to-seven criteria
(n = 43), and beyond preoperative up-to seven criteria (n = 16)
(P = .8).
those receiving preoperative treatments showed 3- and 5-
year DFS rates comparable to those receiving no treatment
(77% and 72% versus 84% and 82%, resp.; P = .2).
Three- and 5-year DFS of patients within preoperative
MC (n = 224), beyond preoperative MC but within up-to-
sevencriteria(n = 43), and beyond preoperative up-to seven
criteria(n = 16)were78%and75%,76%and71%,and81%
and 73%, respectively (P = .8) (Figure 1).
Three- and 5-year DFS of patients within histological
MC (n = 208), beyond histological MC but within up-
to-seven criteria (n = 41), and beyond histological up-
to seven criteria (n = 34) were 83% and 78%, 70% and
70%, and 61% and 58%, respectively (P = .02) (Figure 2).
Preoperative treatments were equally distributed among
these latter categories of patients, being performed in 164
(81%), 32 (82%), and 26 (79%) patients, respectively (P =
.9).
4. Discussion
In the present single-center series of OLT for HCC covering
12 years of activity, we took into consideration several
variables with a hypothetical impact on tumor recurrence.
Some of these factors, such as new dimensional criteria
based on postoperative histology and extending the MC, and
the type of posttransplant immunosuppression, have been
recently reported [6, 11]. However, to our knowledge there
are no other studies considering the classical and the more
recently proposed variables altogether.
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Figure 2: Disease-free survival of patients within histological MC
(n = 208), beyond histological MC but within up-to-seven criteria
(n = 41), and beyond histological up-to seven criteria (n = 34)
(P = .02).
Our series conﬁrmed the still relevant discrepancy
between criteria based on imaging and on ﬁnal histology,
with a substantial proportion of patients being under- or
over-staged before OLT. For over-staged cases, most of the
inconsistencies were ascribable to the adoption of a down-
stagingprotocol[7],butanimportantproportionofpatients
ﬁnally revealed under-staged.
As far as a drastic improvement of radiological imaging
will not be achieved, preoperative and postoperative tumor
morphologies will remain distinct entities, and dimensional
criteria will not be completely reliable, especially when
attempting to extend traditional criteria for OLT.
The up-to-seven threshold proved accurate in antic-
ipating the prognosis when applied postoperatively, as
demonstrated by the diﬀerent outcomes compared to those
of patients within histological MC or beyond MC but within
up-to-seven. However, this novel categorization would have
a limited value if applied to the selection of ideal candidates
to OLT [9].
Contrary to our previous observation [16], fulﬁlling of
preoperativeMCwasnotpredictiveofRFS.Evenifwithalow
number of patients outside the up-to-seven criteria applied
preoperatively, neither of these factors did reach statistical
signiﬁcance at the univariate analysis for RFS.
In general, tumor biology and degree of invasiveness,
as expressed by preoperative AFP values and microvascular
invasion, rather than dimensional parameters showed a
relevant impact on HCC recurrence. In particular, AFP was
the only preoperative variable with an independent impactJournal of Transplantation 7
on RFS. Many diﬀerent cutoﬀso fp r e o p e r a t i v eA F Ph a v e
been reported, ranging from 10 to 1000ng/mL [5, 18–
20]. We set our cutoﬀ at 30ng/mL based on our previous
experience showing optimal discrimination capacity [7, 16]
and on the low median level (9ng/mL) of our study
population, which suggested not to chose higher threshold
values.
On the other hand, microvascular invasion was present
in a very high proportion of our patients and played a critical
role in worsening the outcomes.
Interestingly, preoperative treatments administered with
the purpose of limiting tumor invasiveness led to lower
survival rates. These procedures were extensively applied,
often in combination with each other, either in patients
undergoing down-staging or in those developing multiple
nodules during waiting time; both categories of candidates
are more likely to display tumors exceeding conventional
criteria at histology.
A more limited use of any preoperative treatment in
patients never exceeding preoperative MC has been reported
by our group [7], suggesting that locoregional or surgical
procedures were more often performed in unfavorable cases
with aggressive tumor behavior, while small, single, and/or
slowly growing cancers were frequently left untreated.
However, when looking at 3 diﬀerent risk categories at
ﬁnal histology, such as patients within MC, those beyond
MC and within up-to-seven criteria, and those beyond up-
to-seven criteria, we found that pretransplant treatments
were equally distributed, supporting an independent role
of neoadjuvant procedures in determining the outcomes.
One possible explanation could be the increased tendency
to invasiveness caused by a partial tumor destruction; in
fact, partial necrosis achieved after TACE, PEI, or RF may
enhance tumor spread [21], and this phenomenon has in
turn a higher chance to be observed in larger or multiple
nodules.
Given the acceptable overall results of OLT for HCC at
our center, it is our policy to maximize any tumor treatment,
even with surgical excision (whenever feasible), due to long
waiting periods on list expected for many patients [22]. In
this view, an accurate estimation of the balance between the
harm caused by liver resection in cirrhotic patients and the
beneﬁt oﬀered to patients listed for OLT through a strategy
of primary resection and salvage transplantation has recently
been reported [23].
The role of immunosuppression, and particularly the
use of m-TOR inhibitors with the aim of preventing tumor
recurrence due to the antineoplastic properties of these
drugs, is not yet fully clariﬁed.
Our analysis could not conﬁrm the beneﬁcial eﬀect of
sirolimusontherecurrenceofHCCshownbyrecentreports,
including one from our institution [10, 11]. However, the
study from Vivarelli et al. [11] was a case-control one, with a
particular reference to patients with HCC at a higher risk of
recurrence, that is, those with one or more poor prognostic
factors.Itislikelythatthepositiveeﬀectofm-TORinhibitors
becomes evident in cases of cancers with high tendency to
recur.
5. Conclusions
Weevaluatedtheresultsofour12-yearexperienceofOLTfor
HCC by considering traditional and more recently proposed
prognostic factors for tumor recurrence. In particular, up-
to-seven criteria proved eﬀective in predicting the outcomes
when applied postoperatively, but they showed a negligible
importance if used preoperatively. Biological factors are the
most important determinants of survival, and among them
preoperativetreatmentsmayplayacritical,possiblynegative,
role.
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